1027 EQRx CStone
BioCentury & Getty Images


In third cancer deal, EQRx aims to bring down cost of PD-1, PD-L1 inhibitors

Oct 28, 2020 | 1:45 AM GMT

Through its latest deal with CStone, EQRx is looking to bring lower cost PD-1 and PD-L1 inhibitors to market.

EQRx Inc. launched in January with a $200 million series

Read the full 547 word article

How to gain access

Continue reading with a
two-week free trial.